Cabozantinib tablets | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Cabometyx
Company
Ipsen Pharma (EU authorization holder)
Medicine type
Chemical medicine
Therapeutic area
Oncology
Indications recorded in the public source
EU: Advanced renal cell carcinoma in adults, alone after VEGF-targeted therapy or first line for intermediate/poor-risk disease, or first line with nivolumab. Also hepatocellular carcinoma after sorafenib; progressive locally advanced or metastatic differentiated thyroid cancer after systemic therapy when radioiodine is ineffective or unsuitable; and unresectable or metastatic well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors progressing after at least one systemic therapy other than somatostatin analogues.
Indication source and scope
EU SmPC accessed 2026-11-02; current linked revision. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Overseas official prescribing information linked; a complete current Chinese label has not been verified.
China availability status
Chinese approval, locally approved indications and current availability have not been independently verified in this import.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions